Speaker Profile

Pharm.D., Director of Personalized Medicine and Pharmacogenomics, NorthShore University HealthSystem

Biography
Dr. Dunnenberger is Director of Personalized Medicine and Pharmacogenomics in the Mark R. Neaman Center for Personalized Medicine at NorthShore University HealthSystem (NorthShore), and leads the various clinical implementation projects within the Center. The goal of these projects is to improve the care and health outcomes of NorthShore University HealthSystem patients through genomics-based strategies with a focus on pharmacogenomics. He joined NorthShore in 2014. Dr. Dunnenberger has co-authored over 30 original publications, including multiple CPIC guidelines. He earned his PharmD from the University of Tennessee Health Science Center College of Pharmacy in 2012. He completed a PGY1 Pharmacy Practice Residency at Mission Hospital in Asheville, North Carolina, and a PGY2 Clinical Pharmacogenetics Residency in the Department of Pharmaceutical Sciences at St. Jude Children’s Research Hospital in Memphis, Tennessee.


 Session Abstract – PMWC 2022 Silicon Valley


Track Chairs:
Philip Empey, UPitt
Mary V. Relling, St. Jude Children’s Research Hospital
Stuart Scott, Stanford

Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.

  • Keynote: The Future Of PGx
    - Julie Johnson, University of Florida
  • PGx Research and Discovery
    - Estenab Burchard, UCSF
    - William Evans, St. Jude's
    - Jose Estabil, Cipherome
    - James Coons, UPMC
    - Todd Skaar, Indiana University
  • Innovative Industry Solutions
    - Jeffrey A. Shaman, Coriell Life Sciences
    - Akwasi Asabere, Helix
    - Gillian Bell, Genome Medical
    - Cindy Kosinski, 23andme
  • Key Resources for PGx
    - Kelly E. Caudle, St. Jude Children’s Research Hospital
    - Michelle Whirl-Carillo, Stanford
  • Clinical Laboratory PGx Considerations
    - Ulrich Broeckel, MCW
    - Stuart Scott, Stanford
    - Victoria Pratt, Indiana University
  • Lessons from Frontline PGx Clinical Services
    - Mark H. Dunnenberger, Northshore University HealthSystem
    - Lucas Berenbrok, UPitt
    - Sony Tuteja, UPenn
    - Burns Blaxall, The Christ Hospital Health Network
  • Translational PGx Implementation Programs
    - Philip Empey, UPitt
    - Julie A. Johnson, Uinversity of Florida
    - Mary V. Relling, St. Jude Children’s Research Hospital
    - Laura Ramsey, Cincinnati Children's Hospital
    - Nita A. Limdi, UAB